hero-line-left hero-line-top

What’s new

hero-line-bottom
hero-line-horizontal
temp-hero-icon

Syapse Appoints Dr. Thomas D. Brown as Chief Medical Officer

SAN FRANCISCO – October 16, 2019 – Syapse today announced the appointment of Thomas D. Brown, MD, MBA as its first Chief Medical Officer. Dr…

Read

Syapse Appoints Fletcher Payne as Chief Financial Officer

SAN FRANCISCO – September 10, 2019 – Syapse, a company accelerating precision medicine through insights derived from its global health syste…

Read

The real-world evidence project at the FDA adds Syapse to its list of partners in a push past trial boundaries

8/15/19 - The Oncology Center of Excellence is teaming up with San Francisco-based Syapse to expand beyond electronic health records — or EHRs — in building a multi-sourced program involving data drawn from EHRs and registries, as well as molecular data from testing labs. 

Read

Syapse Announces Research Collaboration with the FDA Focused on the Regulatory Use of Real-World Evidence

SAN FRANCISCO – August 14, 2019 – Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signe…

Read

South Korea’s SNUH extends partnership with Syapse to expand access to precision medicine

8/9/19 - Syapse, a company accelerating precision medicine through insights derived from its global health system network, and Seoul National University Hospital (SNUH) in South Korea announced that they have extended their partnership with a new multi-year agreement. As part of their partnership, SNUH and Syapse will collaboratively work towards building South Korea’s first real-world data sharing network for leading precision oncology hospitals in the region.

Read

Seoul National University Hospital and Syapse Sign Multi-Year Renewal Agreement to Expand Access to Precision Medicine in South Korea

SAN FRANCISCO and SEOUL, SOUTH KOREA - August 6, 2019 - Syapse, a company accelerating precision medicine through insights derived from its…

Read

Syapse Announces Collaboration with Pfizer in Oncology Precision Medicine Focused on Outcomes Research Using Real-World Evidence

SAN FRANCISCO – July 23, 2019 – Syapse, a company accelerating precision medicine through insights derived from its global health syste…

Read

Syapse, Pfizer enter deal to develop precision medicine in oncology

7/23/19 - San Francisco-based Syapse said Tuesday that it had signed a collaboration deal with New York-based drugmaker Pfizer that will involve using real-world data from Syapse’s network of community health system providers to understand molecular testing and treatment choices. The partnership marks the company’s third such deal with a major drug company, after it signed similar agreements with Amgen, in May of this year, and Roche, in January 2018.

Read

Alexander Hardy, CEO of Genentech, Joins Syapse Board of Directors

SAN FRANCISCO - May 29, 2019 - Syapse, a company powering precision medicine through its global provider network, today announced that…

Read

Amgen taps Syapse to infuse real-world data into its cancer clinical trial designs

5/2/19 - Precision medicine company Syapse has launched a collaboration with its one-time Big Pharma benefactor Amgen, with the goal of mining real-world evidence for insights into cancer drug development. Together, Amgen and Syapse will develop observational research analytics aimed at assessing outcomes in areas of unmet need—starting by identifying existing patients within Syapse’s health network that may be eligible for clinical trials, and then bringing those studies to nearby sites.

Read

Amgen and Syapse Enter Precision Medicine Collaboration in Oncology

THOUSANDS OAKS, Calif - May 2, 2019 - Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicin…

Read

Syapse Oncology Platform Achieves HITRUST CSF Certification

SAN FRANCISCO - April 10, 2019 - Syapse, the leader in powering precision medicine through a global health system network, today announ…

Read

Syapse Presents Data Demonstrating the Effectiveness of its Real-World Data Platform in Harmonizing Molecular Testing Results Across Commercial and Hospital-based Laboratories at Scale

SAN FRANCISCO - April 1, 2019 - Syapse, the leader in powering precision medicine through a global health system network, today announc…

Read

Syapse Hosts Inaugural Precision Medicine Council to Drive Progress in Precision Oncology

San Francisco, Calif. (October 18, 2018) – Syapse, the leading precision medicine company, is convening innovative health systems today in S…

Read

Software Veteran James Lim Joins Syapse as Senior Vice President of Product Development

San Francisco, Calif. (July 26, 2018) – Syapse announced today that James Lim has joined the company as Senior Vice President of Product Dev…

Read

Syapse Launches Precision Medicine Council to Advance Health System Adoption of Precision Oncology

San Francisco, Calif. (June 7, 2018) — Syapse, the leading precision medicine company, announced today the formation of the Syapse Precisio…

Read

"Syapse Expands Into Asia With Korean Hospital Deal"

1/31/18 - Syapse, a maker of software to support precision oncology care, has entered the Asian market through a partnership with Seoul National University Hospital. A parallel deal with cloud IT company Megazone will allow the company to reach other potential customers in South Korea, Japan, and Vietnam.

Read

"Medidata, Syapse partner to enhance oncology clinical trials"

2/12/18 - [Syapse and Medidata] will develop a suite of solutions that will increase cancer patients’ access to clinical trials and also assist trial sponsors in designing eligibility criteria and identifying community health systems as trial sites.

Read

"Syapse, Roche partner to further cancer-focused precision medicine"

1/9/18 - Syapse will work with Roche, which includes both pharmaceutical and diagnostics divisions, to develop software and analytics solutions to allow oncologists to practice precision medicine. Per the agreement, Roche will fund the development of the solutions, which will be built on the Syapse platform.

Read

"Syapse raises a $30M Series D round to scale its precision medicine program"

11/14/17 - While Syapse does bring fragmented clinical, molecular, treatment, and health outcomes data together, it also puts an emphasis on collaboration with labs and with companies that specialize in clinical trials. The strength of those relationships is evident in the latest funding round.

Read

"Community providers will help drive the future of precision medicine"

2/23/18 - Mundane and subtle obstacles like insurance models, legacy processes, and siloed data are defining the on-the-ground reality for precision medicine. All of those are issues that community providers are well-positioned to address.

Read

Evolent Health CEO Frank Williams Joins Syapse Board of Directors

San Francisco, Calif. (March 1, 2018) – Syapse, a leading precision medicine company, announced today that Frank Williams, the co-founder an…

Read

Syapse Expands Philadelphia-area Office

San Francisco, Calif. (February 13, 2018) – Syapse, a leader in precision medicine solutions, has expanded its Philadelphia-area location in…

Read

Medidata and Syapse Announce Partnership to Bring Oncology Clinical Trials into Precision Medicine Era

New York and San Francisco, Calif. (January 31, 2018) – Medidata (NASDAQ: MDSO), the leading global provider of cloud-based technology and d…

Read

Syapse Expands Precision Medicine to Asia through Partnerships with Seoul National University Hospital and Megazone

San Francisco, Calif. and Seoul, Republic of Korea (January 30, 2018) – Syapse, a leading precision medicine company, announced today it is…

Read

Syapse Enters Strategic Collaboration with Roche to Advance Precision Medicine in Oncology

San Francisco, Calif. (January 9, 2018) – Syapse, a leading precision medicine company, announced today it has entered into a multi-year str…

Read

Syapse Raises $30 Million to Expand Access to Precision Oncology

San Francisco, Calif. (November 14, 2017) – Syapse, a leader in precision medicine solutions, has raised $30 million in Series D financing,…

Read

"Detroit should serve as model for expanding advanced cancer care"

10/26/17 - Just as Henry Ford himself, perhaps one of the greatest innovators in the modern era, changed how cars were manufactured and made available for large populations more than a century ago, we now want Detroit to be known again for innovation — this time for revolutionizing how cancer care is delivered.

Read

"Q&A With Syapse CEO Ken Tarkoff"

8/11/17 - Our focus is on improving outcomes for cancer patients. We are, at the highest level, doing what we can to improve outcomes.

Read

"Throw out the fax machines: The cancer world needs to modernize molecular test reporting"

7/27/17 - We now know that precision medicine not only works but can lead to better outcomes and quality of life. These benefits will expand exponentially as more providers adopt precision medicine, as they will have a much larger pool of real-world data to inform their insights.

Read

"We could do more to fight cancer like McCain’s. The government won’t let us."

7/25/17 - For us to get closer to a treatment for McCain and the thousands of patients that will come after him, physicians and researchers need to be able to easily share data. We need to tear down the wall between the data so that we can radically reduce the lag between insights and treatment.

Read

"Syapse president: Precision medicine is the reality of cancer care"

6/27/17 - Precision medicine is providing better outcomes and better quality of life for advanced cancer patients today. That is why precision medicine is not only the future of cancer care, but it is also the present reality of cancer care.

Read

"Make no mistake: Cuts to healthcare won’t be superficial "

6/6/2017 - Precision oncology is at a critical inflection point: it’s gaining wide popularity with hospital systems and their oncologists are rushing to make it part of routine cancer care. Now is when we need to be doubling down on precision medicine, accelerating its spread to as many practitioners and patients as we can.

Read

"Aurora Health Care launches Oncology Precision Medicine program"

4/24/17 - The clinic will help clinicians provide more care options for patients using new technology not yet available in Wisconsin called Syapse. Syapse is a leading precision medicine software system bringing together previously fragmented clinical, molecular, treatment and outcomes data to support complex clinical decisions.

Read

Aurora Cancer Care Teams With Syapse to Launch Precision Medicine Program to Bring Greater Cancer Treatment Options to Patients

Milwaukee, Wis. – Aurora Cancer Care and Syapse, a market leader in precision oncology solutions, have teamed to launch…

Read

"Palo Alto startup that fights cancer with software hires CEO"

3/16/17 - Palo Alto-based precision medicine startup Syapse announced Wednesday that it’s hiring former RelayHealth executive Ken Tarkoff as its new CEO.

Read

Precision Medicine Leader Syapse Announces Ken Tarkoff as New CEO

Palo Alto, Calif. (March 15, 2017) – Syapse, a market leader in precision oncology solutions, announced today that Ken Tarkoff is joining th…

Read

Dignity Health and Catholic Health Initiatives Team Up to Launch the Largest Community-Based Precision Medicine Program in the U.S.

SAN FRANCISCO, Calif. and ENGLEWOOD, Colo., September 19, 2016 – Dignity Health and Catholic Health Initiatives (CHI), t…

Read

Henry Ford Health System and Syapse Partner to Launch Cancer Precision Medicine Program

WASHINGTON, D.C., June 29, 2016 - Henry Ford Health System, one of the nation’s leading comprehensive and integrated health system…

Read

Catholic Health Initiatives and Syapse Launch National Cancer Precision Medicine Program

WASHINGTON, D.C.; PALO ALTO, Calif.; ENGLEWOOD, Colo., June 29, 2016 - Catholic Health Initiatives (CHI), the nation’s second-largest nonpro…

Read

Oncology Precision Network (OPeN) Announces Data Sharing Commitments at Vice President Biden's Cancer Moonshot Summit

PALO ALTO, Calif.; SALT LAKE CITY, Utah; RENTON, Wash.; STANFORD, Calif., June 29, 2016 - An initiative to end cancer is getting a boost fro…

Read

TAPUR Study Achieves Milestones: Forty-Nine Patients Consent to Participate, Bayer and Merck Sign on as Drug Providers, and Thirty-Seven Sites Are Participating Twelve Weeks Post-Launch

ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) announced today that Bayer and Merck are the most recent companies t…

Read

ASCO Kicks off Ground-Breaking Clinical Trial to Learn from Use of Approved Targeted Cancer Therapies Matched to Tumor Genomics

ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) today announced it has begun recruiting patients with advanced cancer for…

Read

White House Recognizes Intermountain Healthcare and Syapse for Their Commitment to Precision Medicine

SALT LAKE CITY, Utah and PALO ALTO, Calif., February 26, 2016 – On February 25th, leaders from Intermountain Healthcare, a not-for-profit he…

Read

Syapse Raises $25 Million Series C Round Led by Ascension Ventures to Expand Precision Medicine

PALO ALTO, Calif. and CLAYTON, Mo., January 12, 2016 – Syapse, the leader in precision medicine software, has completed the first close of a…

Read

Caris Life Sciences and Syapse Collaborate to Aggregate Oncology Data that Will Power Precision Medicine and Improve Patient Care

IRVING, Texas and PALO ALTO, Calif., November 18, 2015 – Caris Life Sciences®, a leading biotechnology company focused on fulfilling the pro…

Read

A Groundbreaking Global Alliance Forms to Find Effective Response to the Deadliest Human Brain Tumor

A message from Jonathan Hirsch, Syapse Founder & President: “Each year, tens of thousands of people around the world will receive a diagnos…

Read

Syapse Precision Medicine Platform Selected by Leading Oncology Society to Enable Targeted Agent and Profiling Utilization Registry (TAPUR) Study

PALO ALTO, Calif., June 1, 2015 – Syapse, the leading provider of precision medicine software, announced today that its Syapse Precision Med…

Read

ASCO Launches First-Ever Clinical Trial: Aims to Learn from Patients with Advanced Cancer Who Lack Standard Treatment Options

Five Leading Pharmaceutical Companies Will Support Innovative Study, Contribute Drugs CHICAGO, Ill., June 1, 2015 – The American Society of…

Read

New Studies by Intermountain Healthcare’s Intermountain Precision Genomics Reveal that Precision Medicine Improves Survival in Advanced Cancer Patients without Increasing Costs

SALT LAKE CITY, Utah, May 29, 2015 – Two new studies conducted by Intermountain Healthcare’s Intermountain Precision Gen…

Read